Small molecule · Cytotoxic · developed by UroGen Pharma
UGN-104 is a formulation of mitomycin reconstituted with a sterile, thermally responsive hydrogel. It is liquid when chilled and converts to a semi-solid gel depot after instillation into the upper urinary tract, providing local delivery of mitomycin. It is studied in upper urinary tract urothelial carcinoma and urothelial carcinoma.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06774131 | Phase 3 | Upper Urinary Tract Urothelial Carcinoma | Recruiting | URGN |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Upper Urinary Tract Urothelial CarcinomaUrothelial Carcinoma
Updated Nov 1, 2026. Something wrong or missing? Report it on the URGN page.
See URGN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
URGN catalysts and pipeline →